115 The following table shows the number of shares as of March 31, 2024 owned by directors of the Company as of the date of this annual report. Table of Contents F. Disclosure of a Registrant's Action to Recover Erroneously Awarded Compensation Not applicable. A. Major Shareholders B. Related Party Transactions C. Interests of Experts and Counsel Our audited consolidated financial statements are included under "Item 18—Financial Statements." Takeda's policy in the allocation of capital is as follows: • Inve ...

[Takeda Announces New Director Assignments (Form 6-K)](index=1&type=section&id=Takeda%20Announces%20New%20Director%20Assignments%20(Form%206-K)) Takeda announces new director assignments and governance structure following its 148th Ordinary Meeting of Shareholders [Board of Directors and Governance](index=4&type=section&id=Board%20of%20Directors%20and%20Governance) Takeda announces new director assignments effective June 26, 2024, emphasizing a 14-member board with 11 external directors and independent committee structures - Takeda's Board of Directors consists of 14 members, with a significant majority of **11 being external directors** to ensure transparency and objectivity[9](index=9&type=chunk) - The Audit and Supervisory Committee, Nomination Committee, and Compensation Committee are all composed exclusively of external directors, including their respective chairs[9](index=9&type=chunk) - The new assignments were determined at the Board of Directors meeting and the Audit and Supervisory Committee meeting on June 26, 2024[21](index=21&type=chunk) [Directors (Not Audit and Supervisory Committee Members)](index=4&type=section&id=Directors%20(Not%20Audit%20and%20Supervisory%20Committee%20Members)) This section details assignments for directors not on the Audit and Supervisory Committee, including three internal and seven external directors, with Masami Iijima chairing the Board Meeting Director Assignments (Not Audit and Supervisory Committee Members) | Name | Category | Status | Role | | :--- | :--- | :--- | :--- | | Christophe Weber | Internal | Existing | Representative Director, President & Chief Executive Officer | | Milano Furuta | Internal | New | Director, Chief Financial Officer | | Andrew Plump | Internal | Existing | Director, President, Research & Development | | Masami Iijima | External | Existing | External Director, Chair of the Board Meeting | | Ian Clark | External | Existing | External Director | | Steven Gillis | External | Existing | External Director | | Emiko Higashi | External | New | External Director | | John Maraganore | External | Existing | External Director | | Michel Orsinger | External | Existing | External Director | | Miki Tsusaka | External | Existing | External Director | [Directors (Audit and Supervisory Committee Members)](index=5&type=section&id=Directors%20(Audit%20and%20Supervisory%20Committee%20Members)) All four members of the Audit and Supervisory Committee are external directors, reinforcing independence, with Koji Hatsukawa leading and Jean-Luc Butel newly appointed Director Assignments (Audit and Supervisory Committee Members) | Name | Category | Status | Role | | :--- | :--- | :--- | :--- | | Koji Hatsukawa | External | Existing | External Director, Head of Audit and Supervisory Committee | | Jean-Luc Butel | External | New | External Director, Audit and Supervisory Committee Member | | Yoshiaki Fujimori | External | Existing | External Director, Audit and Supervisory Committee Member | | Kimberly A. Reed | External | Existing | External Director, Audit and Supervisory Committee Member | [Committee Assignments](index=5&type=section&id=Committee%20Assignments) This section details the new membership of the Nomination and Compensation Committees, both exclusively composed of external directors with specific chairs - The Nomination Committee is chaired by Masami Iijima and includes five other external directors: Steven Gillis, Emiko Higashi, Michel Orsinger, Jean-Luc Butel, and Yoshiaki Fujimori[11](index=11&type=chunk) - The Compensation Committee is chaired by Emiko Higashi and includes three other external directors: John Maraganore, Michel Orsinger, and Kimberly A. Reed[25](index=25&type=chunk) [Company Overview and Disclaimers](index=5&type=section&id=Company%20Overview%20and%20Disclaimers) This section provides an overview of Takeda's R&D-driven biopharmaceutical business, along with disclaimers regarding the informational nature of the press release and forward-looking statements - Takeda is an R&D-driven biopharmaceutical company focused on core areas including: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines[25](index=25&type=chunk) - The report contains forward-looking statements subject to significant risks, including economic conditions, competitive pressures, regulatory decisions, clinical success uncertainty, manufacturing delays, and currency fluctuations[15](index=15&type=chunk) - The press release is for informational purposes only and does not constitute an offer to purchase, subscribe for, or exchange any securities in any jurisdiction[13](index=13&type=chunk)[27](index=27&type=chunk)

1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Celiac Disease - Introduction 4.1 Overview 4.2 Regulatory Process This report also provides a detailed analysis of the current celiac disease marketed drugs and late-stage pipeline drugs. Drug Overview Mechanism of Action Regulatory Status Clinical ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Fiscal Year 2023 Earnings Conference Call May 9, 2024 6:00 AM ET Company Participants Christopher O’Reilly – Head-Investor Relations Christophe Weber – President and Chief Executive Officer Andy Plump – President of R&D Milano Furuta – Chief Financial Officer Ramona Sequeira – President of Global Portfolio Division Julie Kim – President of U.S. Business Unit Giles Platford – President, PDT Business Unit Conference Call Participants Steve Barker – Jefferies Hi ...

The most closely comparable measure presented in accordance with IFRS is net profit for the period. Please refer to Net Profit to Adjusted EBITDA Bridge for a reconciliation to the respective most closely comparable measures presented in accordance with IFRS. The most directly comparable measures under IFRS for Net Debt is bonds and loans. Please refer to Net Debt to Adjusted EBITDA for a reconciliation to this measure. A-3 When comparing results to the same period of the previous fiscal year, the amount of ...

Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2024 ________________________________________ TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant's name into English) ________________________________________ 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, To ...

Financial Data and Key Metrics Changes - Revenue for the period was JPY2.1 trillion or $14.1 billion, with year-over-year growth at a constant exchange rate of 1.4% and actual exchange rate growth of 6.4% [8][76] - Core operating profit was JPY588.8 billion or $3.9 billion, reflecting a decline of 9.5% year-over-year at constant exchange rates [27][79] - Core EPS for the period was JPY261, down 14.4% compared to the prior year at constant exchange rates [80][81] Business Line Data and Key Metrics Changes - Growth and launch products represented 42% of total revenue and grew at 13% at constant exchange rates [8][45] - PDT Immunology delivered outstanding growth of 17%, with immunoglobulin growing by 19% and albumin by 11% [52] - Neuroscience grew by 3%, but faced challenges due to generic competition for VYVANSE [85] Market Data and Key Metrics Changes - ENTYVIO maintained its position as the number one treatment in the U.S. for inflammatory bowel disease (IBD), with strong volume growth in the EU at approximately 15% [14][51] - The U.S. IBD market is experiencing suppressed diagnosis and advanced therapy sessions compared to pre-COVID levels, indicating significant opportunities for growth [64][102] - The dengue vaccine QDENGA is seeing strong initial demand in endemic countries and travel markets, with recent approvals in multiple countries [34][38] Company Strategy and Development Direction - The company is focused on maximizing its portfolio, advancing its pipeline, and delivering on commitments, with a commitment to data, technology, and AI to enhance long-term competitiveness [7][25] - The strategy includes pursuing new assets to complement the existing pipeline, particularly in oncology [1] - The company aims to return to revenue, profit, and margin growth in the near term, driven by the expansion of growth and launch products [35][108] Management's Comments on Operating Environment and Future Outlook - Management acknowledged setbacks in the pipeline but emphasized confidence in returning to growth, potentially in 2024 or 2025 [97][108] - The company is committed to maintaining a progressive dividend policy while focusing on sustainable growth and competitive shareholder returns [67][108] - Management highlighted the importance of ongoing investments in R&D and technology to support high-potential programs [87] Other Important Information - The company faced significant non-core items impacting reported operating profit, including impairment losses related to EXKIVITY and ALOFISEL [49][88] - The FDA is evaluating applications for subcutaneous administration of ENTYVIO for Crohn's disease, with a decision expected in the first half of fiscal year 2024 [29][69] Q&A Session Summary Question: Margin expectations for Q3 - Management explained that the core operating profit margin is impacted by product mix and R&D phasing, with expectations aligned to their forecast [61][63] Question: Confidence in returning to growth - Management expressed confidence in returning to growth in 2024 or 2025, depending on the performance of VYVANSE and other factors [96][97] Question: Competitive landscape for ENTYVIO - Management acknowledged intense competition in the IBD market but emphasized ENTYVIO's leading market share and ongoing investments to maintain growth [102][103]

 Our results at constant exchange rate are tracking well against our full year management guidance for fiscal year 2023 and there is no change to our guidance at this time. Looking ahead, we are continuing to work closely with the WHO and look forward to the release of the recommendation from SAGE, the WHO advisory group, which is anticipated later this year. I should also note the important notices are attached to the presentation material. We are proud of all this progress, which represents the potential ...

As filed with the Securities and Exchange Commission on June 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ For the month of June 2023 Commission File Number: 001-38757 TAKEDA ...